BR0112364A - Combinações de bisfosfonatos, agentes estrogênicos e opcionalmente estrogênios - Google Patents

Combinações de bisfosfonatos, agentes estrogênicos e opcionalmente estrogênios

Info

Publication number
BR0112364A
BR0112364A BR0112364-5A BR0112364A BR0112364A BR 0112364 A BR0112364 A BR 0112364A BR 0112364 A BR0112364 A BR 0112364A BR 0112364 A BR0112364 A BR 0112364A
Authority
BR
Brazil
Prior art keywords
optionally
alkyl
estrogens
ethers
bisphosphonates
Prior art date
Application number
BR0112364-5A
Other languages
English (en)
Inventor
Simon Nicholas Jenkins
Barry Samuel Komm
Christopher Paul Miller
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BR0112364A publication Critical patent/BR0112364A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"COMBINAçõES DE BISFOSFONATOS, AGENTES ESTROGêNICOS E OPCIONALMENTE ESTROGêNIOS". Esta invenção compreende processos de tratamento dos distúrbios dos ossos e da diminuição dos níveis de LDL no sangue que compreende a administração de um bisfosfonato e de composto de fórmula (I) ou (IL), em que Z é uma porção selecionado do grupo de (a), (b) ou (c); em que: R~ 1~, é selecionado entre H, OH ou os C~ 1~-C~ 12~ alquil éteres dos mesmos, benzilóxi ou halogênio ou C~ 1~-C~ 4~ éteres halogenados que incluem trifluorometil éter e triclorometil éter; R~ 2~, R~ 3~, R~ 4~, R~ 5~ e R~ 6~ são H, OH ou os C~ 1~-C~ 12~ ésteres OU C~ 1~-C~ 12~ alquil éteres dos mesmos, halogênios ou C~ 1~-C~ 4~ éteres halogenados, ciano, C~ 1~-C~ 6~ alquila ou trifluorometila com a condição de que, quando R~ 1~ for H, R~ 2~ não é OH; Y é a porção (1); R~ 7~ e R~ 8~ são alquila ou concatenados juntos para formar um anel que contenha nitrogênio opcionalmente substituído ou um sal farmaceuticamente aceitável e opcionalmente um estrogênio.
BR0112364-5A 2000-07-06 2001-06-29 Combinações de bisfosfonatos, agentes estrogênicos e opcionalmente estrogênios BR0112364A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21618800P 2000-07-06 2000-07-06
US21606900P 2000-07-06 2000-07-06
PCT/US2001/020970 WO2002003976A2 (en) 2000-07-06 2001-06-29 Combinations of bisphosphonates, estrogenic agents and optionally estrogens

Publications (1)

Publication Number Publication Date
BR0112364A true BR0112364A (pt) 2003-07-29

Family

ID=26910620

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0112364-5A BR0112364A (pt) 2000-07-06 2001-06-29 Combinações de bisfosfonatos, agentes estrogênicos e opcionalmente estrogênios

Country Status (8)

Country Link
EP (1) EP1299093A2 (pt)
JP (1) JP2004502730A (pt)
CN (1) CN1450913A (pt)
AU (1) AU2001273125A1 (pt)
BR (1) BR0112364A (pt)
CA (1) CA2415052A1 (pt)
MX (1) MXPA02012897A (pt)
WO (1) WO2002003976A2 (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6455568B2 (en) 2000-07-06 2002-09-24 Wyeth Combination therapy for inhibiting sphincter incontinence
WO2002003989A2 (en) * 2000-07-06 2002-01-17 Wyeth Use of substituted indole compounds for treating sphincter incontinence
US6376486B1 (en) 2000-07-06 2002-04-23 American Home Products Corporation Methods of inhibiting sphincter incontinence
BR0313182A (pt) 2002-07-24 2007-07-24 Childrens Hosp Medical Center composições e produtos contendo equol enantiomérico
US8668914B2 (en) 2002-07-24 2014-03-11 Brigham Young University Use of equol for treating skin diseases
US8580846B2 (en) 2002-10-29 2013-11-12 Brigham Young University Use of equol for ameliorating or preventing neuropsychiatric and neurodegenerative diseases or disorders
AU2003286781B2 (en) 2002-10-29 2009-05-21 Brigham Young University Use of equol for treating androgen mediated diseases
PT1596870E (pt) † 2002-12-20 2007-10-15 Hoffmann La Roche Formulação com uma dose elevada de ibandronato
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
DK3355884T3 (da) 2015-10-01 2021-08-02 Olema Pharmaceuticals Inc Tetrahydro-1h-pyrido[3,4-b]indol-antiøstrogenlægemidler
CA3008020C (en) 2015-12-09 2024-02-20 The Board Of Trustees Of The University Of Illinois Benzothiophene-based selective estrogen receptor downregulators
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
CN109562107A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的杂环降解决定子体
WO2017197036A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
RU2019102647A (ru) 2016-07-01 2020-08-03 Г1 Терапьютикс, Инк. Антипролиферационные средства на основе пиримидина
WO2018081168A2 (en) 2016-10-24 2018-05-03 The Board Of Trustees Of The University Of Illinois Benzothiophene-based selective mixed estrogen receptor downregulators
JP7229162B2 (ja) 2017-01-06 2023-02-27 ジー１ セラピューティクス， インコーポレイテッド 癌の治療に対する併用療法
CN110461853A (zh) 2017-02-10 2019-11-15 G1治疗公司 苯并噻吩***受体调节剂
BR112019027967A2 (pt) 2017-06-29 2020-07-14 G1 Therapeutics, Inc. forma b cristalina isolada, composição farmacêutica, método para o tratamento de um distúrbio, método de um composto ou composição, e, processo para produzir forma b cristalina.
EP3897631A4 (en) 2018-12-20 2022-11-23 C4 Therapeutics, Inc. TARGETED PROTEIN DEGRADATION
WO2024030968A1 (en) 2022-08-03 2024-02-08 Brystol-Myers Squibb Company Compounds for modulating ret protein
WO2024097989A1 (en) 2022-11-04 2024-05-10 Bristol-Myers Squibb Company Ret-ldd protein degraders
WO2024097980A1 (en) 2022-11-04 2024-05-10 Bristol-Myers Squibb Company Ret-ldd protein inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1080073A1 (en) * 1998-05-15 2001-03-07 American Home Products Corporation Compositions comprising 2-phenyl-indole compounds and estrogen formulations
NZ508200A (en) * 1998-05-15 2003-09-26 Wyeth Corp 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole in combination with estrogens
US6465445B1 (en) * 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors

Also Published As

Publication number Publication date
EP1299093A2 (en) 2003-04-09
CN1450913A (zh) 2003-10-22
JP2004502730A (ja) 2004-01-29
CA2415052A1 (en) 2002-01-17
AU2001273125A1 (en) 2002-01-21
WO2002003976A2 (en) 2002-01-17
WO2002003976A3 (en) 2003-01-03
MXPA02012897A (es) 2003-10-24

Similar Documents

Publication Publication Date Title
BR0112364A (pt) Combinações de bisfosfonatos, agentes estrogênicos e opcionalmente estrogênios
BR0112365A (pt) Combinações de estatinas, agentes estrogênicos e opcionalmente estrogênios
BR0112242A (pt) Composições farmacêuticas de agentes estrogênicos
CA2390295A1 (en) A method for chemoprevention of prostate cancer
BR9815171A (pt) Composto inibidor de pde iv aplicável no tratamento de doenças, particularmente de asma, em mamìferos e método para tratar um paciente sofrendo estados doentios.
BR0208678A (pt) Composto, composição farmacêutica, uso de um composto
BR9809703A (pt) Acilanilidas (hetero) ciclicamente substituìdas, não esteroidais, com eficácia gestagênica e androgênica mista
PT1033981E (pt) Formulacoes e metodos para reduzir a toxicidade de agentes antineoplasicos
EA199700044A1 (ru) Эстрогенные агенты
DK1014966T3 (da) Farmaceutisk præparat til behandling af neurologiske og neuropsykiatriske lidelser
NZ323456A (en) Pharmaceutical composition of an estrogen agonist/antagonist and a prostaglandin or a prostaglandin agonist/antagonist; useful for combination therapy for osteoporosis
ES2180981T3 (es) Procedimiento para la preparacion de una sal de magnesio de un heterociclo de sulfinilo sustituido.
ATE339406T1 (de) Chinazoline verbindungen als heilmittel
AR023423A1 (es) Derivados de adamantano, procedimientos para su preparacion, composicion farmaceutica, procedimiento para la preparacion de la composicion farmaceutica, yuso de dichos derivados para la manufactura de medicamentos
DK279790A (da) Aromatiske steroid-5-alfa-reduktaseinhibitorer
UA41909C2 (uk) Використання комбінації сполук для інгібірування остеопорозу, фармацевтичний препарат
BR9913457A (pt) Neuroproteção
DE60128003D1 (en) Camptothecin derivate
BRPI0417948A (pt) derivados de quinuclidina substituìda por bicicloheterociclo fundido
BR9908510A (pt) Uso de um composto, composto, processo para a preparação de um composto, composição farmacêutica, e, processo de tratar um paciente que sofre de, ou em risco de, uma doença micobacteriana
SE9903997D0 (sv) New compounds
HK1025036A1 (en) Novel cryptophycin derivatives as anti-neoplastic agents
BR9813996A (pt) 2-arilbenzo[b]tiofenos úteis para o tratamento de sìndrome da privação de estrogênio
ATE266029T1 (de) Substituierte pyrrolobenzimidazolderivate zur entzündungshemmung
BR9812780A (pt) 2-aril-3-aroilbenzo[b]tiofenos úteis para o tratamento de sìndrome da perda de estrogênio

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired